Abstract
Millions of deaths worldwide are caused by the aetiological agent of tuberculosis, Mycobacterium tuberculosis. The increasing prevalence of this disease, the emergence of drug-resistant strains, and the devastating effect of human immunodeficiency virus coinfection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. The modern approach to the development of new chemical compounds against complex diseases, especially the neglected endemic ones, such as tuberculosis, is based on the use of defined molecular targets. Among the advantages, this approach allows (i) the search and identification of lead compounds with defined molecular mechanisms against a specific target (e.g. enzymes from defined pathways), (ii) the analysis of a great number of compounds with a favorable cost/benefit ratio, and (iii) the development of compounds with selective toxicity. The present review describes the enzymes of the purine salvage pathway in M. tuberculosis as attractive targets for the development of new antimycobacterial agents. Enzyme kinetics and structural data have been included to provide a thorough knowledge on which to base the search for compounds with biological activity. We have focused on the mycobacterial homologues of this pathway as potential targets for the development of new antitubercular agents.
Keywords: Crystallographic structures, enzyme kinetics, Mycobacterium tuberculosis, nucleotide metabolism, purine salvage pathway, rational drug design, selective toxicity, tuberculosis, drug-resistant, nucleotides
Current Medicinal Chemistry
Title: Purine Salvage Pathway in Mycobacterium tuberculosis
Volume: 18 Issue: 9
Author(s): R. G. Ducati, A. Breda, L. A. Basso and D. S. Santos
Affiliation:
Keywords: Crystallographic structures, enzyme kinetics, Mycobacterium tuberculosis, nucleotide metabolism, purine salvage pathway, rational drug design, selective toxicity, tuberculosis, drug-resistant, nucleotides
Abstract: Millions of deaths worldwide are caused by the aetiological agent of tuberculosis, Mycobacterium tuberculosis. The increasing prevalence of this disease, the emergence of drug-resistant strains, and the devastating effect of human immunodeficiency virus coinfection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. The modern approach to the development of new chemical compounds against complex diseases, especially the neglected endemic ones, such as tuberculosis, is based on the use of defined molecular targets. Among the advantages, this approach allows (i) the search and identification of lead compounds with defined molecular mechanisms against a specific target (e.g. enzymes from defined pathways), (ii) the analysis of a great number of compounds with a favorable cost/benefit ratio, and (iii) the development of compounds with selective toxicity. The present review describes the enzymes of the purine salvage pathway in M. tuberculosis as attractive targets for the development of new antimycobacterial agents. Enzyme kinetics and structural data have been included to provide a thorough knowledge on which to base the search for compounds with biological activity. We have focused on the mycobacterial homologues of this pathway as potential targets for the development of new antitubercular agents.
Export Options
About this article
Cite this article as:
G. Ducati R., Breda A., A. Basso L. and S. Santos D., Purine Salvage Pathway in Mycobacterium tuberculosis, Current Medicinal Chemistry 2011; 18 (9) . https://dx.doi.org/10.2174/092986711795029627
DOI https://dx.doi.org/10.2174/092986711795029627 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hybolites: Novel Therapeutic Tools for Targeting Hyperstructures in Bacteria
Recent Patents on Anti-Infective Drug Discovery Study of the Scientific Production on Leishmaniasis in Latin America
Recent Patents on Anti-Infective Drug Discovery Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Determination of Molecular Properties Effectuating the Growth Inhibition of Mycobacterium Tuberculosis by Various Small Molecule Hydrazides
Letters in Drug Design & Discovery Veterinary Vaccines from Transgenic Plants: Highlights of Two Decades of Research and a Promising Example
Current Pharmaceutical Design Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology A One Pot, Solvent Free and Catalyst Free Synthesis of Substituted 2-Amino-5-Aryl-1,3,4-Oxadiazoles under Microwave Irradiation
Current Microwave Chemistry Synthesis and SAR Evaluation of Mercapto Triazolobenzothiazole Derivatives as Anti-tuberculosis Agents
Anti-Infective Agents Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?
Current Drug Targets The β and γ Classes of Carbonic Anhydrase
Current Pharmaceutical Design Toll-Like Receptors in Human Infectious Diseases
Current Pharmaceutical Design Preface
Current Drug Targets - Infectious Disorders